Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - haemophilus influenzae type b vaccine 10ug (conjugated to tetanus protein (18-30µg)) - injection with diluent - 10 mcg/0.5ml - active: haemophilus influenzae type b vaccine 10ug (conjugated to tetanus protein (18-30µg)) excipient: hydrochloric acid sucrose trometamol sodium chloride water for injection - act-hib is indicated for use in infants from 2 months to 5 years of age for active immunisation against invasive disease caused by the haemophilus influenzae type b.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - tetanus toxoid, quantity: 40 microgram/ml; haemophilus influenza type b polyribose ribitol phosphate, quantity: 20 microgram/ml - injection, powder for - excipient ingredients: water for injections; sodium chloride; lactose - hiberix is indicated for active immunisation against haemophilus influenzae type b infection in children aged from 2 months to 5 years.

Malta - angličtina - Medicines Authority

smithkline beecham limited - haemophilus influenzae b; tetanus toxoid - powder and solvent for solution for infusion - haemophilus influenzae b 25 µg; tetanus toxoid 25 µg - vaccines

Európska únia - angličtina - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), hepatitis b surface antigen, poliovirus (inactivated) (type-1 (mahoney strain), type-2 (mef-1 strain), type-3 (saukett strain)), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines - infanrix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and disease caused by haemophilus influenzae type-b.

Európska únia - angličtina - EMA (European Medicines Agency)

sanofi pasteur msd, snc - purified diphtheria toxoid, purified tetanus toxoid, purified pertussis toxoid, purified pertussis filamentous haemagglutinin, hepatitis b surface antigen, inactivated type 1 poliovirus (mahoney), inactivated type 2 poliovirus (mef 1), inactivated type 3 poliovirus (saukett), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines - this combined vaccine is indicated for primary and booster vaccination of children against diphtheria, tetanus, pertussis, hepatitis b caused by all known subtypes of viruses, poliomyelitis and invasive infections caused by haemophilus influenzae type b.

Európska únia - angličtina - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, inactivated bordetella pertussis, hepatitis b surface antigen (rdna), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; diphtheria - vaccines - quintanrix is indicated for primary immunisation of infants (during the first year of life) against diphtheria, tetanus, pertussis, hepatitis b and invasive disease caused by haemophilus influenzae type b and for booster immunisation of young children during the second year of life.the use of quintanrix should be determined on the basis of official recommendations.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - haemophilus type b polysaccharide, quantity: 10 microgram; tetanus protein, quantity: 18 microgram - injection, powder for - excipient ingredients: trometamol; sucrose - for use in infants from 2 months to 5 years of age for active immunization against invasive disease caused by the haemophilus influenzae type b.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - haemophilus type b polysaccharide, quantity: 10 microgram; tetanus protein, quantity: 18 microgram - injection, powder for - excipient ingredients: trometamol; sucrose - for use in infants from 2 months to 5 years of age for active immunization against invasive disease caused by the haemophilus influenzae type b.

Austrália - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - haemophilus parasuis; thiomersal - misc. vaccines or anti sera - haemophilus parasuis vaccine active 0.0 p; thiomersal mercury other 0.1 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - glassers disease | haemophilus parasuis serovar 13 | haemophilus parasuis serovar 4 | haemophilus parasuis serovar 5 | polyserositis

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

sanofi pasteur - purified diphtheria toxoid ph. eur.; purified tetanus toxoid; adsorbed purified pertussis toxoid; adsorbed purified filamentous haemagglutinin; inactivated poliomyelitis virus ph. eur; inactivated type 1 poliovirus; inactivated type 2 poliovirus; inactivated type 3 poliovirus; haemophilus influenzae type b, conjugate with tetanus protein - powder for suspension for injection - 0.5 millilitre(s) - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus